Insulin Resistance Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 26, 2019--The “Insulin Resistance - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Insulin Resistance - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Involved in Therapeutics Development
- BioElectron Technology Corp
- Caelus Health
- F. Hoffmann-La Roche Ltd
- Lixte Biotechnology Holdings Inc
- NorthSea Therapeutics BV
- Pfizer Inc
- Recursion Pharmaceuticals Inc
Insulin Resistance - Drug Profiles
- BioE-206 - Drug Profile
- CDN-1163 - Drug Profile
- CP-001 - Drug Profile
- englerin A - Drug Profile
- FC-98 - Drug Profile
- Fusion Proteins to Target hOGG1 for Insulin Resistance - Drug Profile
- icosabutate - Drug Profile
- LB-100 - Drug Profile
- RG-7992 - Drug Profile
- sildenafil citrate - Drug Profile
- Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
- Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
- Small Molecules for Immunology, Metabolic Disorders and Musculoskeletal Disorders - Drug Profile
- Small Molecules for Inherited Insulin Resistance Syndrome - Drug Profile
- SYM-401 - Drug Profile
- TM-25659 - Drug Profile
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mhnzfs/insulin?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190326005714/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/26/2019 11:22 AM/DISC: 03/26/2019 11:22 AM